Pharma IQ Members

Compound Screening

Compound Screening is defined as the identification of compounds that could be promising candidates for drug development, before it advances to the more-costly stages of preclinical and clinical trials. Compound Screening is also done to identify the potential side effects caused by administration of such compound(s).

EU-OPENSCREEN: A Future Pan-European Research Infrastructure for Chemical Biology; Sharing Samples, Expertise and Knowledge for the Discovery of Bioactive Small Molecules

Dr. Ronald Frank, Head of Research Group, Chemical Systems Biology, Leibniz- Institut fur Molekulare Pharmakologie (FMP), speaks to Pharma IQ about the EU-OPENSCREEN project initiative, funding and plans. EU-OPENSCREEN, the European...

Wed, 09/14/2011
Pharma IQ News

An efficient and versatile compound management operation is essential for the success of all downstream processes in high throughput screening (HTS) and small molecule development.  The 6th Compound Management & Integrity conference taking...

Contributor: Pharma IQ News
Thu, 08/26/2010
Pharma IQ
In this exclusive interview, Dr. Sylviane Boucharens, Section Head of Molecular Pharmacology Department at MSD, speaks to Andrea Charles from Pharma IQ, about the current hurdles to accurate compound management and integrity, and the benefits of...
Contributor: Pharma IQ
Mon, 08/16/2010